TY - JOUR
T1 - Human Milk Oligosaccharides and Hispanic Infant Weight Gain in the First 6 Months
AU - Berger, Paige K.
AU - Plows, Jasmine F.
AU - Jones, Roshonda
AU - Alderete, Tanya L.
AU - Yonemitsu, Chloe
AU - Ryoo, Ji Hoon
AU - Bode, Lars
AU - Goran, Michael I.
PY - 2020
Y1 - 2020
N2 - Objective: The aim of this study was to determine whether human milk oligosaccharides (HMOs) at 1 month predicted infant weight gain at 6 months and whether associations varied by HMO secretor status. Methods: Participants were 157 Hispanic mother-infant pairs. Human milk samples were collected at 1 month. Nineteen individual HMOs were analyzed using high-performance liquid chromatography, and secretor status was determined by the presence of 2′-fucosyllactose or lacto-N-fucopentaose (LNFP) I. Infant weight was measured at 1 and 6 months. Path analysis was used to test effects of HMO composition on infant weight gain, adjusting for maternal age, prepregnancy BMI, and infant age, sex, and birth weight. Results: In the total sample, higher LNFPII predicted lower infant weight gain (g1 = −4.1, P = 0.004); this was observed in both nonsecretor (g1 = −3.0, P = 0.006) and secretor groups (g1 = −4.7, P = 0.014). In the nonsecretor group, higher lacto-N-neotetraose (g1 = 7.6, P = 0.011) and disialyllacto-N-tetraose (g1 = 14.3, P = 0.002) predicted higher infant weight gain. There were no other associations in the secretor group. Conclusions: Our data suggest that higher LNFPII in human milk may decrease obesity risk across all infants, whereas higher lacto-N-neotetraose and disialyllacto-N-tetraose may increase obesity risk in infants of nonsecretors only.
AB - Objective: The aim of this study was to determine whether human milk oligosaccharides (HMOs) at 1 month predicted infant weight gain at 6 months and whether associations varied by HMO secretor status. Methods: Participants were 157 Hispanic mother-infant pairs. Human milk samples were collected at 1 month. Nineteen individual HMOs were analyzed using high-performance liquid chromatography, and secretor status was determined by the presence of 2′-fucosyllactose or lacto-N-fucopentaose (LNFP) I. Infant weight was measured at 1 and 6 months. Path analysis was used to test effects of HMO composition on infant weight gain, adjusting for maternal age, prepregnancy BMI, and infant age, sex, and birth weight. Results: In the total sample, higher LNFPII predicted lower infant weight gain (g1 = −4.1, P = 0.004); this was observed in both nonsecretor (g1 = −3.0, P = 0.006) and secretor groups (g1 = −4.7, P = 0.014). In the nonsecretor group, higher lacto-N-neotetraose (g1 = 7.6, P = 0.011) and disialyllacto-N-tetraose (g1 = 14.3, P = 0.002) predicted higher infant weight gain. There were no other associations in the secretor group. Conclusions: Our data suggest that higher LNFPII in human milk may decrease obesity risk across all infants, whereas higher lacto-N-neotetraose and disialyllacto-N-tetraose may increase obesity risk in infants of nonsecretors only.
UR - https://dx.doi.org/10.1002/oby.22884
U2 - 10.1002/oby.22884
DO - 10.1002/oby.22884
M3 - Article
VL - 28
JO - Obesity
JF - Obesity
IS - Issue 8
ER -